November 14, 2017
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
October 24, 2017
Combination therapy will be the most effective treatment for Alzheimer’s disease. Learn why they hold such promise and why Amylyx's drug is the first such therapy we are funding.
October 24, 2017
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
September 13, 2017
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
September 5, 2017
At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.
August 17, 2017
A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.
March 7, 2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
January 10, 2017
In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.
January 9, 2017
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
September 29, 2016
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."